Figure 4.

MnTnBuOE-2-PyP⁵⁺ (BMX-001) in four Phase II clinical trials. MnTnBuOE-2-PyP⁵⁺ was shown safe and well tolerated in a Phase I trial on glioma patients [13] and was then forwarded into Phase II trials. Initial data from the Phase I trial suggest the therapeutic potential of MnTnBuOE-2-PyP⁵⁺ with glioma patients [14, 15]. None of the nine patients receiving MnTnBuOE-2-PyP⁵⁺/temozolomide developed dose-limiting thrombocytopenia in the Phase I clinical trial [14]. Three other trials are ongoing on the radioprotection of normal tissue with head and neck cancer patients, anal squamous cell carcinoma patients, and patients with multiple brain metastases.